Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05890001 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
A Phase 3 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT05890001 is a Phase 3 study that has completed, run by Braintree Laboratories. The registered enrollment target is 400 participants.
The verdict
NCT05890001, a Phase 3 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
Interventions
- DRUG BLI5100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-04-05 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05890001
The ClinicalTrials.gov registry entry for NCT05890001 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BLI5100 is the first listed.
NCT05890001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05890001 about?
NCT05890001 is a clinical study titled "A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease". The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
What is the current status of trial NCT05890001?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2023-04-05. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT05890001?
The interventions under investigation include: BLI5100 (DRUG).
Who is sponsoring clinical trial NCT05890001?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.